C-反应性蛋白加速动脉样硬化的进展在apolipoprotein E缺乏的小鼠中
Antoni Paul1, Kerry W S Ko, Lan Li
1Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Baylor College of Medicine, Houston, Tex 77030, USA.
Circulation
|January 28, 2004
概括
人类C反应蛋白 (CRP) 加快小鼠动脉样硬化. 这项研究提供了体内证据,证明CRP促进大动脉病变的发展,增加其大小和细胞炎症标志物.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 血C反应蛋白 (CRP) 是已知的动脉样硬化的预测因子.
- 之前的研究缺乏体内证据来证实CRP的益风性作用.
研究的目的:
- 研究人类CRP转基因表达对阿波利波蛋白E缺陷小鼠动脉样硬化发展的体内影响.
主要方法:
- 使用了具有人类CRP转基因 (tg) 的阿波利波蛋白E缺陷 (apoE-/-) 小鼠.
- 在基底和泥刺激条件下评估动脉样硬化.
- 分析了大动脉动脉样硬化病变的大小,C3沉积,血管细胞粘附分子-1,原蛋白和血管素1型受体 (AT1-R) 表达.
主要成果:
- 人类CRP转基因表达在apoE-/-小鼠中显著增加了大动脉动脉样硬化病变大小.
- 在病变内,CRP和补充C3沉积量升高.
- 在表达CRP的小鼠的病变中观察到AT1-R,血管细胞粘附分子-1和原的表达增加.
- 没有注意到血压的显著差异,这表明局部影响.
结论:
- 人类CRP转基因表达在apoE-/-小鼠中加速大动脉动脉样硬化.
- 在体内,CRP是益风性,与补体激活和在动脉样硬化病变内增加炎症标记物和AT1-R的表达有关.
相关概念视频
Inflammation
Overview
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


